Drug intelligence / Profile preview

NMJ-2

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

NMJ-2 is a novel small molecule histone deacetylase (HDAC) inhibitor, specifically a cinnamyl sulfonamide-hydroxamic acid derivative. It has been investigated for its neuroprotective properties in preclinical models of neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease. NMJ-2 works by inhibiting HDAC enzymes, which leads to a reduction in oxidative stress and neuroinflammation, the restoration of striatal dopamine levels, and the protection of neuronal cells from amyloid-beta (Aβ)-induced neurodegeneration. In animal models, such as the MPTP-induced rat model of Parkinson's, NMJ-2 has demonstrated the ability to improve locomotor and anxiety-like behaviors.

Other names: cinnamyl sulfonamide-hydroxamic acid derivative

Targets

HDAC (HDAC family)

Beyond the preview

Go deeper on NMJ-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMJ-2.

Explore the full profile